Objectives: To determine natural phenotypic susceptibility of non-group M HIV-1 to integrase strand transfer inhibitors (INSTIs) in a large panel of 39 clinical strains from groups O, N and P and to identify genotypic polymorphisms according to susceptibility levels.
Introduction
HIV-1 is classified into four groups, M, N, O and P, but only HIV-1 group M (HIV-1/M) is pandemic. HIV-1 non-group M (HIV-1/non-M) strains are endemic in west-central Africa, especially in Cameroon, where HIV-1 group O (HIV-1/O) represents 0.6%-1% of HIV diagnoses; HIV-1 group N (HV-1/N) and HIV-1 group P (HIV-1/P) are rarer, with fewer than 20 and 1 reported infections, respectively. [1] [2] [3] Sporadic cases of HIV-1/O have also been reported elsewhere in Africa, the USA and Europe. Cases of HIV-1/O, HIV-1/N and HIV-1/P have been detected in France via a national survey network, which has identified more than 130 cases of HIV-1/O infection, a primary HIV-1/N infection and the new prototype strain of group P. 4, 5 HIV-1/O group is characterized by high intra-group genetic diversity, leading to this group being further classified into two subgroups (H and T), and marked natural genetic polymorphism, relative to HIV-1/M, in ART targets. Thus, HIV-1/O has shown natural genotypic and phenotypic resistance to NNRTIs, caused by the presence of the natural mutation, Y181C. [6] [7] [8] [9] The greatest polymorphism has been reported in the protease (PR) region with more than 15 mutations at resistance-associated positions described in HIV-1/M; although the impact on phenotypic susceptibility is uncertain, there are discrepancies in the interpretation of genotypic resistance for nelfinavir, tipranavir and saquinavir. 10 Concerning the gp41 region, the signature mutation of HIV-1/O (N42D) has been associated with genotypic resistance to enfuvirtide, but phenotypic data indicated full susceptibility. 11 This natural genetic diversity leads to limited therapeutic options, thus challenging the choice of fully active ART for efficient treatment in HIV-1/O-infected patients.
The development of integrase strand transfer inhibitors (INSTIs) has presented new opportunities for HIV-1/O-infected patients, V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
leading to the assessment of HIV-1/O genetic diversity. Analysis of natural polymorphism in the HIV-1/O integrase region revealed four highly prevalent mutations (L74I, S153A, V201I, T206S) among 19 positions associated with resistance (using the ANRS algorithm, http://www.hivfrenchresistance.org), but with no impact on genotypic resistance. 12, 13 Limited clinical data, based only on the use of raltegravir, have shown this drug can be effective. 14, 15 Recently, phenotypic studies have shown the susceptibility of HIV-1/O to INSTI, but these data were obtained without testing the most recent drug, dolutegravir, or involved a limited number of strains. [16] [17] [18] Concerning HIV-1/N and HIV-1/P, no data are available on the integrase natural polymorphism of the strains and their phenotypic susceptibility to INSTIs, or on the patients' response following clinical use of INSTIs.
The aims of this work were twofold: first, to determine the phenotypic susceptibility of a large and diverse panel of HIV-1/ non-M strains to the three drugs currently available, raltegravir, elvitegravir and dolutegravir; and second, to investigate the potential relationship between the level of phenotypic susceptibility and genetic polymorphisms.
Patients and methods

Strains
We studied 39 clinical strains isolated from INSTI treatment-naive HIV-infected patients, representative of HIV-1 non-M diversity: 36 HIV-1/O (25 from subgroup H, 11 from subgroup T), 2 HIV-1/N and 1 HIV-1/P (Figure 1 ). The HIV-1/M BRU-HXB2 strain (accession number K03455) was used as a reference.
Strains were isolated from plasma (spinoculation) or amplified from already available supernatants (amplification), as previously described. 10 Briefly, PBMCs from healthy donors were separated by Ficoll-Hypaque (GE Healthcare, Velizy-Villacoublay, France) through a density gradient and stimulated with phytohaemagglutinin for 3 days. Then, 20 million PBMCs were incubated for 2 h with 80 lL infected plasma or 500 pg RT activity (Lenti RT activity assay, Cavidi, Uppsala, Sweden) of virus stock supernatant, washed twice with RPMI medium containing gentamicin, and resuspended at 1%10 6 cells/mL in production media (RPMI, 10% decomplemented fetal bovine serum, 50 lg/mL gentamicin, 2 lg/mL polybrene, 540 IU/mL IL-2r). Half of the volume was replaced with fresh media twice a week and RT activity was carried out to determine the maximal peak of viral production needed for the phenotypic assay.
Phenotypic assay
The phenotypic assay was performed as previously described. 19 Briefly, fresh phytohaemagglutinin-stimulated PBMCs were infected with 100 TCID 50 of cell-free HIV-1 supernatant for 2 h. Infected PBMCs were then washed and seeded at 2%10 6 cells/mL in a 96-well plate (four wells per infection and condition) containing five serial dilutions of the antiretroviral drugs: dolutegravir and elvitegravir at 0, 0.1, 1, 10, 100 and 1000 nM; and raltegravir at 0, 0.11, 1.1, 11, 110 and 1100 nM. After 3 days, replication was measured on the pools of four wells per condition by real-time quantitative RT-PCR; total nucleic acid extraction was performed on a MagNA Pure LC (Roche Diagnostics, Mannheim, Germany) using the Large Volume Isolation Kit (Roche Diagnostics, Mannheim, Germany). Quantification was performed using tools adapted to each group due to the genetic divergence of the strains: Generic HIV Viral Load (Biocentric, Bandol, France) for HIV-1/N strains or quantitative RT-PCR targeting of the integrase region for HIV-1/O strains or the LTR for HIV-1/P. [20] [21] [22] We then calculated the drug concentrations that 7 Phylogenetic analyses were performed using the neighbour-joining method, and evolutionary distances calculated with the Kimura two-parameter method. Testing of the inferred phylogeny was performed with a 1000 replication bootstrap method. The integrase region sequences are all available from GenBank: accession numbers MF084892 to MF084930.
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inhibited strain replication by 50% (IC 50 ) and the fold change (FC); the interpretation of the FC was based on a threshold of 2.5.
Sequencing of the integrase region
Amplification of the integrase coding region (codons 19-263) was performed by nested RT-PCR on each strain supernatant. The primers used are listed in Table 1 and the technical conditions for the RT-PCR and Sanger sequencing were as previously described.
12,23
INSTI resistance-associated mutations
Non-M amino acid sequences were aligned against the HIV-1/M reference sequence BRU-HXB2 using Bioedit software 7.2.5 (Ibis Biosciences, Carlsbad, CA, USA). INSTI resistance-associated mutations (RAMs) were those in the lists defined in the resistance algorithms of the ANRS 2016 (http://www.hivfrenchresistance.org/), Rega v.9.1.0 (http://rega.kuleuven. be/cev/avd/software/rega-algorithm), Stanford v8.1.1 (http://hivdb.stan ford.edu) and in the IAS-USA 2017 update (https://www.iasusa.org/). Substitutions at resistance positions previously described in HIV-1/non-M were also considered.
12,24
Statistical analyses
Statistical analyses were performed and figures generated using GraphPad Prism software (San Diego, CA, USA). Signature pattern analysis in the integrase amino acid sequences of each strain was performed using the Vespa Program (Viral Epidemiology Signature Pattern Analysis, https://www.hiv. lanl.gov/content/sequence/VESPA/vespa.html). 25 Residue frequencies were analysed using Fisher's exact test, with a significance threshold of P , 0.05.
Results
Phenotypic results
Among the 39 non-M strains, the mean IC 50 for raltegravir of the two HIV-1/N strains and the IC 50 of the one HIV-1/P were 0.44 and 0.98 nM, respectively. For the 36 HIV-1/O strains, the IC 50 values ranged from 0.003 to 3.82 nM, with a mean and median of 0.86 and 0.51 nM, respectively; a difference between the means obtained for the H and T subgroups was observed (Figure 2a) . The mean and median FC relative to the reference strain BRU-HXB2 (IC 50 " 1.68 nM), were 0.51 and 0.30, respectively; seven strains (18%) had an FC .1 [mean of 1.62 (range 1.07-2.28), median of 1.63], but none had a FC above the considered threshold of 2.5.
The IC 50 for dolutegravir was extremely low for the HIV-1/N and P strains, ,0.04 nM (Figure 2b ). For the HIV-1/O strains, the IC 50 values ranged from below 0.0001 to 3.89 nM, with a mean and median of 0.78 and 0.30 nM, respectively; these values were also dependent on the subgroup, but inversely to the situation with raltegravir (Figure 2b) . The mean and median FC, relative to the reference strain BRU-HXB2 (IC 50 " 2.09 nM), were 0.37 and 0.14, respectively; five strains (13%) showed a mean and a median FC .1 of 1.35 (range 1.03-1.86) and 1.30, respectively, but as for raltegravir, none had an FC .2.5.
The mean IC 50 for elvitegravir of the two HIV-1/N strains and the IC 50 of the one HIV-1/P were 0.09 and 1.14 nM, respectively. For the HIV-1/O strains, the IC 50 values ranged from below 0.0001 to 3.54 nM, with a mean and median IC 50 of 0.77 and 0.46 nM, respectively; these values were independent of the subgroup (Figure 2c) . The IC 50 of the HIV-1/M reference strain BRU-HXB2 IC 50 was 0.2 nM. Thus, in contrast to the case with raltegravir and dolutegravir, we found a higher number of strains (n " 20, 51%) with 
Genotypic results
We observed a high rate of natural polymorphism among HIV-1/O strains, with 18 (41%) positions harbouring mutations among the 44 positions associated with resistance (Table 2) ; mutations L74I, T124A, S153A, V201I and T206S were found at very high frequencies (94%-100%). We also found atypical residues (i.e. mutations found at resistance positions, but not known to confer resistance) S119P, K160S, G163Q and S195T at high frequencies (.89%). 
Mutation C280Y was not considered because of amplification of the integrase region up to position 263 only.
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Globally, HIV-1/N and HIV-1/P strains exhibited less polymorphism than HIV-1/O (Table 2 ), but the three groups shared three mutations associated with resistance (V72I, T124A and V201I), and three atypical mutations (T112V, S119P and S195T) ( Table 2) . Of note, V165I was only found in HIV-1/N strains.
Despite these polymorphisms, we found no genotypic resistance (according to the ANRS, IAS-USA, Stanford and Rega predictive algorithms) among the three groups, except for the major mutation T97A (in 1 HIV-1/O strain), conferring resistance to elvitegravir and raltegravir; L68V (in 7 strains) as a miscellaneous INSTIassociated mutation in the Stanford rules; and the T124A and T206S mutations (in 37 and 35 strains, respectively) with a weak score in the Rega rules for dolutegravir and raltegravir, respectively.
The DDE-catalytic domain (D64G, D116G and E152K) was highly conserved among the strains (data not shown).
The phenotypic results for elvitegravir led us to search for a link between FC .2.5 and a specific genotypic pattern. We determined the number of strains naturally harbouring mutations at positions associated with resistance among the 39 non-M strains, according to three groups of FC values (FC 10, 2.5,FC,10 and FC 2.5) ( Table 3 ). There were eight positions with mutations associated with resistance in the six strains with an FC 10, which were also found among the strains with an FC ,10; only an atypical L68I and the mutation T97A were found as a single mutations in two distinct high-FC strains (Table 3) . Among the 2.5,FC,10 group, we found atypical residues (M50R, K160A, G163L/E, I203T) only encountered in this group, but each was found in only one strain. We then performed a comparative analysis using VESPA, considering all positions of the sequence, including those not associated with resistance, for the three groups of FC. We found residues at positions (50 and 72) described to be associated with group M resistance, but also at positions that have not (63, 173, 200, 222 and 224) ( Table 4 ). The highest values (FC 10) were characterized by the pattern V72I, I200L, N222K and R224Q, irrespective of the groups compared (Table 4) ; supplementary mutations M50I and L63M were identified when comparing strains with an FC below versus those above 10, but the association was not significant (P . 0.05).
Discussion
Here, we showed the overall natural phenotypic susceptibility to raltegravir, elvitegravir and dolutegravir of 39 HIV-1 non-M clinical strains, including rare samples from groups N and P, with a particular elvitegravir profile for some strains.
Phenotypic analyses revealed globally similar extended ranges of IC 50 results between the three drugs, not observed previously due to the very limited number of HIV-1/O strains (n " 3). 18 We also showed strain-dependent differences in the IC 50 between drugs. Indeed, the distribution of IC 50 values was different between raltegravir, elvitegravir and dolutegravir depending on the HIV-1/O subgroups: we observed higher means for subgroup T for raltegravir and subgroup H for dolutegravir, with no difference for elvitegravir. Although there were no virological or clinical consequences, these data show that the susceptibility level depends on the variant, as already observed in HIV-1/M subtypes, and differs, according to the drug. 26 We observed differences in the FC values between raltegravir and dolutegravir (all strains had an FC ,2.5), and elvitegravir, with a more heterogeneous distribution and FC 10 for 15% of the panel, irrespective of the subgroup. This result may be linked to the lower IC 50 value (0.2 nM) obtained for our reference strain, HIV-1/M BRU-HXB2, with elvitegravir, relative to those for 
FC 10 (n"6) 2 6 6 6 6 6 6 2.5,FC,10 (n"12) Mutations known to be associated with resistance are shown in bold; atypical residues found at resistance positions are not bold. HIV-1/non-M susceptibility to INSTI JAC raltegravir and dolutegravir (1.68 and 2.09 nM, respectively). Apart from the apparent hypersensitivity of the reference strain to elvitegravir, these results are consistent with those previously obtained using a similar method. 24, 27, 28 Using a very different method to compare the susceptibility of 9 HIV-1/M strains with a panel of 19 HIV-1/O strains, Tebit et al. 16 obtained for group M strains a range of IC 50 values of 0.01-0.7 nM with elvitegravir, confirming the heterogeneity of susceptibility level to this drug. Nonetheless, the mean IC 50 for these M strains was 0.14 nM, very close to the value obtained for our reference strain (0.2 nM). In addition, this study showed no difference in raltegravir susceptibility profiles between group M and O strains (mean IC 50 of 23.7 and 40.1 nM, respectively), whereas there was a significant difference for elvitegravir (mean IC 50 of 0.14 and 1.57 nM, respectively), with 16 of 19 HIV-1/ O strains having an IC 50 above the mean IC 50 of the HIV-1/M strains. These differences in the IC 50 values are consistent with our FC results and confirm the heterogeneous susceptibility profile for elvitegravir among non-M strains. Several distinct mechanisms may cause susceptibility differences for this drug; for example, natural polymorphisms may contribute to conformational changes in the enzyme structure, affecting intrinsic properties.
The genotypic analysis showed an HIV-1/O signature polymorphism (L74I, T124A, S153A, V201I, T206S)-previously described in part-but also showed, for the first time, the natural polymorphism of HIV-1/N and P, which is less marked than that of HIV-1/O.
12 Surprisingly, although HIV-1/P has the same origin as group O, a simian immunodeficiency virus found in gorillas, the polymorphism of the integrase region seems to be closer to that of HIV-1/N, the origin of which is chimpanzee. 29 The very low number of group P and N strains in this study was only sufficient to show a trend.
Based on predictive resistance algorithms, these polymorphisms do not appear to have a direct impact on natural genotypic susceptibility to INSTIs. This is consistent with data in INSTI-naive patients infected with HIV-1/M non-subtype B for whom the similar prevalent substitutions, V72I, T124A, V201I, and T206S, were also found, whereas we did not observe L101I, highly prevalent in these non-subtype B strains. 28, 30 Given the phenotypic results for elvitegravir, we attempted to determine the relationship between the highest FC values and genotypic determinants. We failed to find a pattern of resistance mutations described for HIV-1/M. However, analysis of the whole sequence of the integrase region allowed the identification of a specific set of mutations (V72I, I200L, N222K and R224Q) associated with the highest FC values. Site-directed mutagenesis analyses are now necessary to determine the impact of these specific residues.
Further studies are also necessary to determine the resistance pathways of these divergent strains relative to HIV-1/M by analyzing (i) the impact of known HIV-1/M resistance mutations in these non-M backgrounds, (ii) the emergence of specific patterns in tissue-culture drug selection and (iii) selected mutations in vivo in patients in whom the virus is under INSTI pressure.
In conclusion, the main strength of our work was the large and diverse panel of HIV-1/non-M strains, allowing for the first time a description of the phenotypic susceptibility of N and P strains to INSTI. Our phenotypic data show that non-M strains are globally susceptible to the three current INSTIs, although data on elvitegravir revealed that some strains have a higher FC, the impact of which needs to be explored. Clinical data are now needed to confirm these phenotypic results. The VESPA analysis displays the most common amino acid in the target set compared with the background by calculation of amino acid frequencies.
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